Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 10Osteosarcoma 3Ganglioneuroblastoma 3Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Medulloblastoma 1Glioma 1Glioblastoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1

Interventions

Irinotecan 7Cyclophosphamide 7Vincristine 6Magnetic Resonance Spectroscopy 5Dactinomycin 5temsirolimus 4cixutumumab 4X-Rays 4Sirolimus 4Radiotherapy 4Phantoms, Imaging 4Etoposide 4Doxorubicin 4Specimen Handling 3Radiation 3Peripheral Blood Stem Cell Transplantation 3Nuclear Medicine Department, Hospital 3Melphalan 3Ifosfamide 3Gemcitabine 3Filgrastim 3ulixertinib 2tipifarnib 2thymoglobulin 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Rhabdomyosarcoma × dinutuximab × Clear all
NCT04238819 2026-03-02

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Eli Lilly and Company

Phase 1/2 Completed
47 enrolled 36 charts
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡